Navigation Links
WuXi PharmaTech Completes Acquisition of AppTec
Date:1/31/2008

SHANGHAI, China, Jan. 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX) today announced the completion of its acquisition of AppTec Laboratory Services, Inc., a US-based service provider for the biopharmaceutical and medical device industries. AppTec offers testing, contract research and development, and cGMP biologics manufacturing services from a highly differentiated, fully integrated platform.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The combined company brings together complementary service offerings and expertise to create a broad platform covering both chemistry and biologics, which allows WuXi PharmaTech to provide value-added services to our customers in the pharmaceutical, biotechnology and medical device industries.

"We are pleased to have completed this significant acquisition which immediately adds biologics capabilities and expertise to WuXi PharmaTech's existing capabilities, gains a significant U.S. operational footprint for WuXi PharmaTech and expands our U.S. customer base, with further opportunities to increase our market position," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This acquisition further solidifies our leadership position as the premier and preferred drug R&D service partner for pharmaceutical, biotechnology and medical device companies."

"The management teams and dedicated employees of both companies are very enthusiastic about the prospects of the combined company," commented Mr. Edward Hu, COO of WuXi PharmaTech. "This is an acquisition of capabilities that we believe will drive our future growth by positioning WuXi as a high quality global drug R&D service collaborator with both small and large molecules expertise."

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and research manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2007, its 80 customers included nine of the world's top ten pharmaceutical companies by revenue. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Hai Mi, Ph.D.

Vice President, Corporate Communications

WuXi PharmaTech Co., Ltd.

Tel: +86-21-5046-3726

Fax: +86-21-5046-3718

Email: mi_hai@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
2. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
3. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
4. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
5. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
6. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
7. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
8. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
9. WuXi PharmaTech Announces Second Quarter 2007 Results
10. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
11. Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):